Treatment options

Who should treat you

Before what, the more important question is where. Intimal sarcoma sits between specialties — cardiothoracic or vascular surgery, medical oncology, radiation oncology, pathology, radiology — and almost no individual doctor has treated more than a handful of cases. Every current review makes the same first recommendation: management in a specialised sarcoma center with a multidisciplinary tumour board.¹¹¹ That board should include a surgeon who has operated inside the pulmonary artery or aorta before. See how to find a sarcoma center.

The evidence base is small and almost entirely retrospective — there has never been a randomised trial in this disease. What follows is what the literature supports, in plain language, so that you can follow the reasoning of your own team.

Surgery: the only treatment that can cure

Complete surgical removal is the only potentially curative treatment for intimal sarcoma, and complete removal (R0, clear margins) is the single strongest predictor of long survival in every series.¹²³ In the pooled analysis of 643 pulmonary artery sarcoma patients, 81% had surgery, and surgery extended survival at every stage.²

For pulmonary artery tumours the operations used are:³⁴¹¹

• Resection and reconstruction of the pulmonary trunk and main pulmonary arteries — the involved segment is removed and replaced, often with a homograft (donor vessel) — performed on cardiopulmonary bypass. In one specialised series this "anatomic resection" approach achieved clear margins in 45% of patients, with an operative mortality of 10%, and a median survival of 2.8 years from diagnosis.³
• Pulmonary endarterectomy (PEA) — the operation developed for chronic clots, in which the tumour is peeled out of the artery. It is often the operation that is performed when the disease is still thought to be a clot. One 20-patient series reported a perioperative mortality of 15%.⁴
• Pneumonectomy (removal of a lung) when the tumour extends far into one lung's arteries — needed in about a third of patients in one series.³

Cardiac intimal sarcomas are removed by open-heart surgery; aortic tumours by resection and graft replacement of the involved segment. Questions worth asking your surgeon are on our checklist — above all: how many of these have you done, and what is the realistic chance of clear margins?

Chemotherapy

The best data on drugs come from the World Sarcoma Network, which pooled 72 MDM2-positive intimal sarcoma patients from 17 reference centers in Europe, the United States and Japan.⁵

The conclusion of that study — and of the 2026 review — is that anthracycline-based chemotherapy is the most active systemic treatment known, and that multimodal therapy (surgery plus chemotherapy, with or without radiotherapy) may improve outcomes in selected patients.¹⁵ Notably, anthracyclines were given to 26 patients with cardiac intimal sarcoma without significant heart toxicity being reported.⁵

Chemotherapy is used in three situations: after surgery (adjuvant) to reduce the risk of recurrence, before surgery (neoadjuvant) to shrink a tumour, and for advanced or recurrent disease. Which applies to you, and whether the expected benefit outweighs the side effects, is a tumour-board decision.

Radiotherapy

Radiotherapy is used before or after surgery to improve local control, and to treat recurrences or metastases that cannot be operated on.⁶ There is no trial evidence specific to intimal sarcoma; its use follows general sarcoma practice and the judgement of the treating center. Modern techniques (including proton therapy in some centers) allow high doses close to the heart and great vessels with less damage to surrounding tissue.

Targeted drugs: aimed at MDM2, CDK4 and PDGFRA

Intimal sarcoma is defined by amplification of specific genes — MDM2 in about two thirds of cases, CDK4 and PDGFRA in a large proportion, and in some tumours the alternatives MDM4 or CDK6.¹² Each of these is, in principle, a drug target:

• MDM2 inhibitors (brigimadlin, milademetan, navtemadlin and others) block the protein that MDM2-amplified tumours use to switch off the p53 "brake". They are being tested mainly in dedifferentiated liposarcoma and in baskets of MDM2-amplified solid tumours; early-phase studies have included patients with various MDM2-amplified cancers.⁹ None is approved for intimal sarcoma, and access is currently through clinical trials.
• CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved for breast cancer and have shown activity in CDK4-amplified liposarcoma in a phase 2 trial.⁸ In intimal sarcoma the evidence is limited to case reports and biological rationale: a 2025 multi-omics study found CDK4 gains or CDKN2A losses in 81% of 31 intimal sarcomas and concluded that CDK4/6 inhibitors warrant clinical investigation.⁷
• PDGFRA-directed tyrosine kinase inhibitors (imatinib, pazopanib, others) have a clear rationale in PDGFRA-amplified tumours, but the only series to test pazopanib found a response rate of 8%.⁵

Because these decisions depend entirely on what your tumour carries, the molecular report is not a formality — it is the map. If you do not have one, ask for it (what it should contain). Off-label use of a targeted drug is sometimes possible through a molecular tumour board; ask whether your center has one.

Immunotherapy

Checkpoint inhibitors (PD-1/PD-L1 antibodies) have transformed some cancers but have modest activity in most sarcomas. Intimal sarcomas typically have a low mutational burden, which usually predicts poor response. Yet the picture is not settled: in the 2025 multi-omics study, PD-L1 was positive in 6 of 8 evaluable tumours, pulmonary artery tumours showed substantial immune-cell infiltration, and two patients who received a PD-1 inhibitor after surgery had survived 14+ and 56+ months at reporting.⁷ These are tiny numbers, not proof — but enough for the authors to call for clinical investigation.

The practical takeaway: ask whether PD-L1 and tumour mutational burden were measured on your tumour, and whether an immunotherapy trial is an option for you.

Clinical trials — and why they are hard to find

At the time of writing, a search of ClinicalTrials.gov for recruiting studies that name intimal sarcoma explicitly returns one trial — a risk-adapted study in non-rhabdomyosarcoma soft tissue sarcomas for children and young adults.¹⁰ That is the state of the field.

The realistic routes into a trial are therefore:

• Basket trials for MDM2-amplified or "solid tumour" cohorts, where eligibility is defined by the molecular alteration rather than the diagnosis. Search ClinicalTrials.gov for "MDM2", "CDK4" or "sarcoma" plus your country, and ask your sarcoma center to check eligibility.
• Sarcoma-wide trials that accept "other soft tissue sarcoma" or "ultra-rare sarcoma" (the EU and US sarcoma groups run several).
• Precision-oncology programmes at large centers (for example NCT Heidelberg's MASTER programme in Germany), which sequence the tumour and match it to trials or off-label options.

One of the goals of this initiative is to give trial sponsors what they currently lack: a documented, molecularly characterised group of patients that makes it worth including intimal sarcoma in a study. Every case added to the case base makes that argument stronger.

Follow-up after treatment

Because recurrence is common (see prognosis), follow-up is part of treatment. Typical practice is CT of the chest (and abdomen/pelvis) every three to four months in the first two years, sometimes with FDG-PET/CT or cardiac MRI, then at longer intervals. Ask for your schedule in writing, and report new breathlessness, chest pain, cough or weight loss promptly rather than waiting for the next scan.

Frequently asked